Sign In to Follow Application
View All Documents & Correspondence

An Ex Vivo Animal Surrogate Model For Studying Human Hair Development

Abstract: The present disclosure relates to a method of ex-vivo growth of goat skin hair follicles as an animal model for human hair growth and development. The present disclosure also relates to a culture medium composition for development of an ex-vivo system for growth and development of goat skin derived hair follicles.

Get Free WhatsApp Updates!
Notices, Deadlines & Correspondence

Patent Information

Application #
Filing Date
25 October 2013
Publication Number
19/2015
Publication Type
INA
Invention Field
PHARMACEUTICALS
Status
Email
lsmds@lakshmisri.com
Parent Application

Applicants

ITC LIMITED
ITC Life Sciences & Technology Centre, Peenya Industrial Area, No. 3, 1st Main, 1 st Phase , Bangalore 560 058

Inventors

1. ACHARYA, Aviseka
ITC Life Sciences & Technology Centre, Peenya Industrial Area, No. 3, 1st Main, 1 st Phase, Bangalore 560 058
2. HEGDE, Ashok
ITC Life Sciences & Technology Centre, Peenya Industrial Area, No. 3, 1st Main, 1 st Phase, Bangalore 560 058
3. KALSI, Gurpreet
ITC Life Sciences & Technology Centre, Peenya Industrial Area, No. 3, 1st Main, 1 st Phase, Bangalore 560 058

Specification

DESC:AN EX-VIVO ANIMAL SURROGATE MODEL FOR STUDYING HUMAN HAIR DEVELOPMENT ,CLAIMS:1. A method for ex-vivo growth of goat skin hair follicles for study of human hair development, wherein the method comprises of:
a. isolating goat skin sections with hair follicles,
b. antibiotic and antimycotic treatment of isolated goat skin sections with hair follicles,
c. digestion of isolated goat skin sections with hair follicles with collagenase,
d. isolating intact goat skin hair follicles from goat skin sections, and
e. culturing of isolated goat skin hair follicles in a culture medium
2. The method as claimed in claim 1, wherein the goat skin sections with hair follicles is isolated from a group of animals that are in the age-range of 6 – 8 months, preferably 7 months.
3. The method as claimed in claim 1, wherein the goat skin sections with hair follicles is isolated from the group of body parts consisting of back side and tail, preferably tail.
4. The method as claimed in claim 1, wherein the isolated goat skin sections with hair follicles is treated with antibiotics and antimycotics selected from the group consisting of aminoglycosidal, bacteriostatic antimicrobial, broad spectrum polyketide antibiotic , amphotericin B, and polyene antifungal, preferably amphotericin B, aminoglycosidal, broad spectrum polyketide antibiotic, and bacteriostatic antibacterial.
5. The method as claimed in claim 4, wherein the antibiotic and antimycotic treatment is for a time period is 60 – 90 minutes, preferably 60 minutes.
6. The method as claimed in claim 4, wherein the concentration of the antibiotic and antimycotic is in the range of 30X – 50X, preferably 50X.
7. The method as claimed in claim 1, wherein concentration of collagenase is in the range of 3%-6%, preferably 3%.
8. The method as claimed in claim 1, wherein the isolated goat skin sections with hair follicles is digested with collagenase for a time period ranging from 3-4 hours, preferably 4 hours.
9. The method as claimed in claim 1, wherein the goat skin sections with hair follicles is digested at 370C.
10. The method as claimed in claim 1, wherein the goat skin sections with hair follicles is digested under CO2 concentration ranging from 4%-6%, preferably 5%.
11. A culture medium comprising of basal medium, antibiotic/antimycotic solution, gentamycine, chloramphenicol, tetracycline, kanamycin, amikacin, hydrocortisone, insulin and insulin transferrin selenium.
12. The culture medium as claimed in claim 11, wherein the basal medium is William’s E medium.
13. The culture medium as claimed in claim 11, wherein the concentration of the antibiotic/antimycotic solution is in the range of 1X-2X, preferably 2X.
14. The culture medium as claimed in claim11, wherein the antimycotic in the antibiotic/antimycotic solution is amphoterecin B.
15. The culture medium as claimed in claim 11, wherein the concentration of gentamycin is in the range of 100µg/mL-200µg/mL, preferably 100µg/ml.
16. The culture medium as claimed in claim 11, wherein the concentration of chloramphenicol is in the range of 50µg/mL-100µg/mL, preferably 100µg/mL.
17. The culture medium as claimed in claim 11, wherein the concentration of tetracycline is in the range of 25µg/mL-100µg/mL, preferably 25µg/mL.
18. The culture medium as claimed in claim 11, wherein the concentration of kanamycin is in the range of 50µg/mL-100µg/mL, preferably 50µg/mL.
19. The culture medium as claimed in claim 11, wherein the concentration of amikacin is in the range of 50µg/mL-100µg/mL, preferably 50µg/mL.
20. The culture medium as claimed in claim 11, wherein the concentration of hydrocortisone is in the range of 50µg/mL-100µg/mL, preferably 50µg/mL.
21. The culture medium as claimed in claim 11, wherein concentration of insulin is in the range of 50µg/mL100µg/mL, preferably 100µg/mL.
22. The culture medium as claimed in claim11, wherein the concentration of insulin transferrin selenium is in the range of 1X-3X, preferably 1X.
23. The culture medium as claimed in claim 11, wherein the pH of the culture medium is in the range of 7.4-7.6, preferably 7.4.
24. A method for ascertaining if a test compound is capable of modulating hair follicle activity, comprising contacting said test compound with a hair follicle grown in the culture medium as claimed in claim 11, measuring hair follicle activity parameters, and comparing said parameters to results from hair follicle grown said culture medium without contacting with said test compound.

Documents

Application Documents

# Name Date
1 4829-CHE-2013-FER.pdf 2019-12-19
1 SPEC IN.pdf 2013-10-29
2 PD009748IN-SC_Seuence listing_ST25.txt 2013-10-29
2 Form 18 [12-01-2017(online)].pdf 2017-01-12
3 FORM 3.pdf 2013-10-29
3 4829-CHE-2013 CORRESPONDENCE OTHERS 25-06-2014.pdf 2014-06-25
4 4829-CHE-2013 FORM-5 25-06-2014.pdf 2014-06-25
4 FIGURES IN.pdf 2013-10-29
5 FIG IN PCT.pdf 2014-04-11
5 4829-CHE-2013 POWER OF ATTORNEY 26-12-2013.pdf 2013-12-26
6 SPEC N.pdf 2014-04-11
6 4829-CHE-2013 FORM-1 26-12-2013.pdf 2013-12-26
7 4829-CHE-2013 CORRESPONDENCE OTHERS 26-12-2013.pdf 2013-12-26
8 SPEC N.pdf 2014-04-11
8 4829-CHE-2013 FORM-1 26-12-2013.pdf 2013-12-26
9 FIG IN PCT.pdf 2014-04-11
9 4829-CHE-2013 POWER OF ATTORNEY 26-12-2013.pdf 2013-12-26
10 4829-CHE-2013 FORM-5 25-06-2014.pdf 2014-06-25
10 FIGURES IN.pdf 2013-10-29
11 4829-CHE-2013 CORRESPONDENCE OTHERS 25-06-2014.pdf 2014-06-25
11 FORM 3.pdf 2013-10-29
12 PD009748IN-SC_Seuence listing_ST25.txt 2013-10-29
12 Form 18 [12-01-2017(online)].pdf 2017-01-12
13 SPEC IN.pdf 2013-10-29
13 4829-CHE-2013-FER.pdf 2019-12-19

Search Strategy

1 searchstrategy_10-12-2019.pdf